An Airline, Biotechs, and More See Huge Insider Buying
Public offerings of stock and activist investor activity prompted some huge insider buying at an entertainment company, an airline, biotechs, and more.
Headquartered in Norwood, MA Fiscal year ends December NASDAQ: CRBP corbuspharma.com
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing new therapies in oncology and obesity. The company's pipeline includes CRB-701, a next-generation Nectin-4 targeting antibody drug conjugate (ADC) licensed from CSPC Megalith Biopharmaceutical, being developed for oropharyngeal squamous cell carcinoma and cervical cancer, with FDA Fast Track designations for both indications. The second pipeline asset is CRB-913, an orally delivered, highly peripherally restricted CB1 inverse agonist for the treatment of obesity, designed with a mechanism of action distinct from the GLP-1 receptor agonist class. The company is pre-revenue and funds operations through equity capital, with a cash runway expected into 2028. Corbus trades on NASDAQ under the ticker CRBP. Updated
Public offerings of stock and activist investor activity prompted some huge insider buying at an entertainment company, an airline, biotechs, and more.
A public offering of shares this past week prompted a huge purchase from a beneficial owner. Meanwhile, a couple of repeat buyers further boosted their stakes as well.
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA | NVDA Price Prediction) to the forefront of the industry.…
Warren Buffett boosts his stake in this tracking stock again, plus notable insider buying of communication and aviation stocks in the past week.
Another huge Warren Buffett purchase highlighted the past week's insider buying, and a couple of IPOs also prompted insiders to action.
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
Robinhood has become the dominant discount brokerage platform over the last year. It had 4.3 million average revenue trades in June, which is a critical metric in the industry. This is higher…
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing new therapies in oncology and obesity.
The Wall Street consensus 12-month price target for CRBP is $34.02.